Moderna’s mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe—but it continues ...
Stocks are set to close out April with major gains even as a war in the Middle East is ongoing, and fears around AI ...
TheFly reported on April 9 that B. Riley Financial increased its price target on NVAX from $16 to $18 while maintaining a Buy ...
Zacks Investment Research on MSN
European Commission approves mRNA's COVID-19-influenza combo shot
Moderna MRNA reported that the European Commission (EC) has granted marketing authorization for mCombriax (mRNA-1083), its ...
In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for ...
A phase 3 study of Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate has been initiated. Read more ...
The biotech sector is having another one of its moments—the kind that sends retail investors scrambling for the sidelines ...
A first-of-its-kind trial has been launched to test a new vaccine for bird flu in humans.Thousands of people in the UK are ...
The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...
The Department of Health and Human Services had canceled hundreds of millions of dollars in funding previously committed to ...
Moderna said on Tuesday it had started a late-stage study of its experimental bird flu vaccine in the U.S. and the UK, ...
The cancer antigen therapy mRNA-4359 yielded a high rate of antitumor responses in combination with pembrolizumab (Keytruda) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results